Value
7.6/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 5.4 |
| Analyst target | 9.0 |
- ▸Attractively valued
BBNX · Why this verdict
Why Beta Bionics (BBNX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Beta Bionics is a fast-growing but cash-burning insulin-pump maker, with revenue up about 30% YoY and four straight earnings beats offset by weak quality, heavy insider selling and customer concentration.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Business quality is weak: free cash flow is about -32% of revenue and operating margin is about -29%, so the company depends on its cash cushion to fund growth. Warnings | Cash burn as a share of revenue narrows materially as scale builds over 12 months. | ↓Deteriorating |
| CounterContinued losses could force dilutive financing, and margin compression is already flagged as a value-trap signal. | ||
Revenue is compounding quickly, with quarterly revenue rising from $27.3M to $35.5M year over year, consistent with strong growth of 30% YoY. Growth breakdown | Quarterly revenue keeps growing at 20%+ YoY over the next 12 months. | →Stable |
| CounterGrowth is concentrated in a single product and a few distributors, so a stumble in one channel could stall the growth rate. | ||
The company has beaten EPS estimates in each of the last 4 quarters, with an average surprise of about 33%, showing losses narrowing faster than analysts expect. Earnings | Losses per share continue to come in better than consensus over the next 4 quarters. | →Stable |
| CounterBeats against low, loss-making estimates are easy to deliver, and earlier quarters missed badly (-84% and -124% surprises). | ||
Revenue depends on a single product (iLet) and the top four durable-medical-equipment distributors account for 52.0% of sales, creating concentration risk. Bear case | Distributor concentration declines and the customer base broadens over 12 months. | ↓Deteriorating |
| CounterConcentrated distributors give the company scale access to patients quickly; losing one would still be a large hit. | ||
Insiders sold about $3.1M of stock over 90 days with no buys, while short interest is 13% and the put/call ratio is 1.50, pointing to cautious positioning. Insider | Insider selling fades and the put/call ratio falls toward 1.0 if confidence returns. | →Stable |
| CounterSales may be routine, pre-planned and tied to equity compensation rather than a view on the business, and analysts still see 30% upside to target. | ||
Business quality is weak: free cash flow is about -32% of revenue and operating margin is about -29%, so the company depends on its cash cushion to fund growth.
↓DeterioratingWarnings
- Expectation
- Cash burn as a share of revenue narrows materially as scale builds over 12 months.
CounterContinued losses could force dilutive financing, and margin compression is already flagged as a value-trap signal.
Revenue is compounding quickly, with quarterly revenue rising from $27.3M to $35.5M year over year, consistent with strong growth of 30% YoY.
→StableGrowth breakdown
- Expectation
- Quarterly revenue keeps growing at 20%+ YoY over the next 12 months.
CounterGrowth is concentrated in a single product and a few distributors, so a stumble in one channel could stall the growth rate.
The company has beaten EPS estimates in each of the last 4 quarters, with an average surprise of about 33%, showing losses narrowing faster than analysts expect.
→StableEarnings
- Expectation
- Losses per share continue to come in better than consensus over the next 4 quarters.
CounterBeats against low, loss-making estimates are easy to deliver, and earlier quarters missed badly (-84% and -124% surprises).
Revenue depends on a single product (iLet) and the top four durable-medical-equipment distributors account for 52.0% of sales, creating concentration risk.
↓DeterioratingBear case
- Expectation
- Distributor concentration declines and the customer base broadens over 12 months.
CounterConcentrated distributors give the company scale access to patients quickly; losing one would still be a large hit.
Insiders sold about $3.1M of stock over 90 days with no buys, while short interest is 13% and the put/call ratio is 1.50, pointing to cautious positioning.
→StableInsider
- Expectation
- Insider selling fades and the put/call ratio falls toward 1.0 if confidence returns.
CounterSales may be routine, pre-planned and tied to equity compensation rather than a view on the business, and analysts still see 30% upside to target.
Per-dimension breakdown
Quality
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 7.7 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 7.2 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -32% of revenue
- ▸Quality concerns
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 30% YoY
Momentum
2.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 0.6 |
| OBV | 1.0 |
| MA position | 3.0 |
| Volume | 1.2 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.0 |
| Analyst rating | 7.2 |
| Price target | 9.7 |
- ▸Analyst upside: 58%
Insider
3.7/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 6.1 |
- ▸Notable insider selling — $3,107,644 (0.341% of mkt cap)
Peer rank
5.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.1 |
| quality rank | 1.1 |
| growth rank | 8.4 |
- ▸Industry growth leader
- ▸Conservative debt levels
Technical
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.8 |
| support resistance | 10.0 |
| 52w position | 0.0 |
Risk (lower is worse)
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.6 |
| days to cover | 5.8 |
| volatility | 0.0 |
| put call | 6.0 |
| implied vol | 0.0 |
| debt equity | 9.9 |
- ▸High IV: 135%
- ▸Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- ASYMMETRY:2.5>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:106d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:2.3<4.5
- INSIDER:0.34%=HEAVY
Warning (0)
none
Reward-to-Risk
2.49
Upside
+37.3%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.9B) below institutional reach
SuitabilitySpeculative — Drawdown -51% (>40% off 52w high)
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.3<4.5 outcome against Growth at 10.0 and asymmetric R:R of 2.49.
The strongest dimensions are Growth at 10.0, Value at 7.6, and Catalyst at 7.6; the weakest are Momentum at 2.3, Quality at 3.0, and Insider at 3.7. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 2.49 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Rapid Revenue Growth
Trip ifQuarterly revenue growth falls below 15% YoY for 2 consecutive quarters.
- P2Consistent Earnings Beats
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P3Cash Burn Weak Quality
Trip ifFree cash flow burn exceeds 40% of revenue from the current 32%.
- P4Customer Product Concentration
Trip ifTop four distributors' share of sales rises above 60% from 52.0%.
- P5Insider Selling And Sentiment
Trip ifNet insider selling over 90 days exceeds $6M with 0 purchases.